CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial\*

|  |  |  |  |
| --- | --- | --- | --- |
| Section/Topic | Item No | Checklist item | Reported on page No |
| Title and abstract |
|  | 1a | Identification as a pilot or feasibility randomised trial in the title | 1 |
| 1b | Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials) | 1-2 |
| Introduction |  |  | Introduction |
| Background and objectives | 2a | Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial | 2-3 |
| 2b | Specific objectives or research questions for pilot trial | 3-4 |
| Methods |
| Trial design | 3a | Description of pilot trial design (such as parallel, factorial) including allocation ratio | 4 |
| 3b | Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons |  |
| Participants | 4a | Eligibility criteria for participants | 4-5 |
| 4b | Settings and locations where the data were collected | 4+6 |
|  | 4c | How participants were identified and consented | 6 |
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 13-15 |
| Outcomes | 6a | Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed | 5  |
| 6b | Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons | 22-23 |
|  | 6c | If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial | 21 |
| Sample size | 7a | Rationale for numbers in the pilot trial | 5 |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines | n.a |
| Randomisation: |  |  |  |
| Sequence generation | 8a | Method used to generate the random allocation sequence | n.a |
| 8b | Type of randomisation(s); details of any restriction (such as blocking and block size) | n.a |
| Allocationconcealmentmechanism | 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | n.a |
| Implementation | 10 | Who generated the random allocation sequence\*, who enrolled participants, and who assigned participants to interventions | \*n.a |
| Blinding | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how | n.a |
| 11b | If relevant, description of the similarity of interventions | n.a |
| Statistical methods | 12 | Methods used to address each pilot trial objective whether qualitative or quantitative |  |
| Results |
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective | n.a |
| 13b | For each group, losses and exclusions after randomisation, together with reasons | n.a |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up | 4 |
| 14b | Why the pilot trial ended or was stopped | n.a |
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group | 17-18 |
| Numbers analysed | 16 | For each objective, number of participants (denominator) included in each analysis. If relevant, these numbersshould be by randomised group | 5, 16-22 |
| Outcomes and estimation | 17 | For each objective, results including expressions of uncertainty (such as 95% confidence interval) for anyestimates. If relevant, these results should be by randomised group | 21 |
| Ancillary analyses | 18 | Results of any other analyses performed that could be used to inform the future definitive trial | n.a |
| Harms | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) | n.a |
|  | 19a | If relevant, other important unintended consequences | 22-23 |
| Discussion |
| Limitations | 20 | Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility | 25-30 |
| Generalisability | 21 | Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies | 27 |
| Interpretation | 22 | Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, andconsidering other relevant evidence | 30 |
|  | 22a | Implications for progression from pilot to future definitive trial, including any proposed amendments | 25-30 |
| Other information |  |
| Registration | 23 | Registration number for pilot trial and name of trial registry | 2 |
| Protocol | 24 | Where the pilot trial protocol can be accessed, if available | n.a |
| Funding | 25 | Sources of funding and other support (such as supply of drugs), role of funders | 32 |
|  | 26 | Ethical approval or approval by research review committee, confirmed with reference number | 33 |